Meeting
2022 ASCO Annual Meeting
CaboMain: A phase 2 study of cabozantinib as a maintenance agent in patients with ultra-high risk pediatric solid tumors.
Authors
Nilay Shah
Nationwide Children's Hospital, Columbus, OH
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Pediatric Oncology
Track
Pediatric Oncology
Sub Track
Pediatric Solid Tumors
Clinical Trial Registration Number
NCT05135975
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr TPS10060)
DOI
10.1200/JCO.2022.40.16_suppl.TPS10060
Abstract #
TPS10060
Poster Bd #
273a
Abstract Disclosures
Similar Posters
Poster
2021 ASCO Annual Meeting
Open label phase II trial of cabozantinib (cabo) in patients with metastatic castrate resistant prostate cancer (mCRPC) and known amplifications or activating mutations in gene targets who have received prior anti-androgen therapy.
First Author: Jones T. Nauseef
Poster
2017 ASCO Annual Meeting
Phase II study of cabozantinib (cabo) in patients (pts) with recurrent/metastatic endometrial cancer (EC): A study of the Princess Margaret, Chicago, and California phase II consortia.
First Author: Neesha C. Dhani
Poster
2015 ASCO Annual Meeting
Biomarker analysis of a phase II trial of cabozantinib and erlotinib in patients (pts) with EGFR-mutant NSCLC with epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) resistance: A California Cancer Consortium Phase II Trial (NCI 9303).
First Author: Karen L. Reckamp
Poster
2014 ASCO Annual Meeting
Phase II study of XL184 (cabozantinib) in recurrent or metastatic endometrial cancer: A trial of the PMH, Chicago, and California Phase II Consortia.
First Author: Michelle Wilson